News: Johnson & Johnson (JNJ)

JNJ on New York Consolidated

102.20USD
24 Jul 2014
Price Change (% chg)

$0.01 (+0.01%)
Prev Close
$102.19
Open
$102.34
Day's High
$102.73
Day's Low
$102.02
Volume
5,177,227
Avg. Vol
6,348,262
52-wk High
$106.74
52-wk Low
$85.50

Search Stocks
Select another date:

Tue, Jul 15 2014

US STOCKS-Wall St dips after Yellen comments on valuations

* New York manufacturing hits highest level since April 2010

J&J beats forecasts, helped by new hepatitis C drug

- Johnson & Johnson reported higher-than-expected quarterly results on sizzling sales of its new Olysio treatment for hepatitis C, but company officials cautioned the pill will lose steam later this year as newer rivals come to market.

UPDATE 3-J&J beats forecasts, helped by new hepatitis C drug

July 15 - Johnson & Johnson reported higher-than-expected quarterly results on sizzling sales of its new Olysio treatment for hepatitis C, but company officials cautioned the pill will lose steam later this year as newer rivals come to market.

Obama meets with CEOs of Goldman Sachs, others, on family issues

WASHINGTON - President Barack Obama met with Goldman Sachs Chief Executive Lloyd Blankfein, Johnson & Johnson chief Alex Gorsky and other business leaders on Monday to discuss ways to encourage companies to make their work places more family friendly.

Obama meets with CEOs of Goldman Sachs, others, on family issues

WASHINGTON, June 23 - President Barack Obama met with Goldman Sachs Chief Executive Lloyd Blankfein, Johnson & Johnson chief Alex Gorsky and other business leaders on Monday to discuss ways to encourage companies to make their work places more family friendly.

Medtronic to buy Covidien for $42.9 billion, rebase in Ireland

- U.S. medical device maker Medtronic Inc said on Sunday it had agreed to buy Covidien Plc for $42.9 billion in cash and stock and move its executive base to Ireland in the latest transaction aiming for lower corporate tax rates abroad.

J&J links up with GSK-led group on new two-drug HIV tablet

LONDON, June 12 - Johnson & Johnson has linked up with ViiV Healthcare - a specialist HIV company majority-owned by GlaxoSmithKline - to develop a new AIDS medicine combining two drugs in a single tablet.

Pharmacyclics, J&J drug shown to improve leukemia survival

CHICAGO - A new drug for the most common form of leukemia in adults improves survival for patients whose disease has worsened despite standard treatment, according to late-stage study findings released on Saturday.

UPDATE 1-Pharmacyclics, J&J drug shown to improve leukemia survival

CHICAGO, May 31 - A new drug for the most common form of leukemia in adults improves survival for patients whose disease has worsened despite standard treatment, according to late-stage study findings released on Saturday.

Pharmacyclics, J&J drug shown to improve leukemia survival

CHICAGO, May 31 - A new drug for the most common form of leukemia in adults improves survival for patients whose disease has worsened despite standard treatment, according to late-stage study findings released on Saturday.

Select another date:
Search Stocks